A Phase III Clinical Trial of An Inactivated Quadrivalent Influenza Vaccine in Healthy Subjects Aged 3 Years and Older

Influenza Clinical Trial

Official title:

A Double-blind,Randomized,Positive-controlled, Non-inferiority Phase III Clinical Trial of An Inactivated Quadrivalent Influenza Vaccine (Split Virion) in Healthy Chinese Subjects Aged 3 Years and Older

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02710409
• Other study ID #: JSVCT031
• Status: Completed
• Phase: Phase 3
• First received: March 12, 2016
• Last updated: August 30, 2016
• Start date: January 2016
• Est. completion date: August 2016

Study information

• Verified date: August 2016
• Source: Jiangsu Province Centers for Disease Control and Prevention
• Contact: n/a
• Is FDA regulated: No
• Health authority: China: Food and Drug Administration
• Study type: Interventional

Clinical Trial Summary

Influenza is an acute respiratory disease caused by influenza viruses. There are three types of the virus including A, B and C. Both type A and type B viruses can cause acute febrile respiratory tract infection, characterized by sudden fever, headache, muscle pain, cough, sore throat, nasal congestion and general malaise. The main transmission of influenza is through those highly contagious aerosol droplets containing influenza virus passed from infected people to susceptible population. Each year in the fall and winter infection of influenza is widespread in various age groups, with high incidence rate. Although influenza is generally a self-limiting disease, but in children, the elderly (especially those above 65 years old and those with chronic heart, lung, kidney, liver, blood or metabolic diseases such as diabetes or other certain diseases) and those with poor immunity function, influenza can easily lead to serious flu complications such as pneumonia, resulting in severe increase of morbidity and mortality.

In order to evaluate safety and immunogenicity of a quadrivalent influenza vaccine produced by Jiangsu Jindike Biotechnology Co., Ltd. a phase III clinical trial is planned to conduct in healthy Chinese subjects aged 3 years and older.

Description:

Subjects will be randomized into three arms- Experimental Group, Active Comparator A and Active Comparator B by the ratio of 2:1:1.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 3664
• Est. completion date: August 2016
• Est. primary completion date: June 2016
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Both
• Age group: 3 Years and older

Eligibility

Inclusion Criteria:

• Aged 3 years and older

• Healthy subjects judged from medical history and clinical examination

• Subjects themselves or their guardians able to understand and sign the informed consent

• Subjects themselves or their guardians can and will comply with the requirements of the protocol

• Subjects with temperature <=37.0°C on axillary setting

Exclusion Criteria:

• Subject who has a medical or family history of any of the following: allergic history, seizure, epilepsy, brain or mental disease

• Any prior administration of influenza vaccine in last 6 month

• Subject who is allergic to any ingredient of the vaccine

• Female subject aged =18 years with a positive result after urine pregnancy test or during pregnancy or baby nursing period

• Subject with damaged or low immune function which has already been known

• Subject who had a seasonal influenza medical history in last 6 months

• Subject with acute febrile illness or infectious disease

• Major congenital defects or serious chronic illness, including perinatal brain damage

• Thrombocytopenia, blood coagulation disorder or bleeding difficulties with intramuscular injection

• Subject who has serious allergic history

• Subject with other medical history not suitable for vaccination such as fainting during injection

• Any prior administration of immunodepressant or corticosteroids in last 6 months

• Any prior administration of blood products in last 3 months

• Any prior administration of other research medicine/vaccine in last 30 days

• Any prior administration of any attenuated live vaccine in last 30 days

• Any prior administration of subunit or inactivated vaccines in last 14 days, such as pneumococcal vaccine

• Any medical, psychological, social or other condition judged by investigator, that may interfere subject's compliance with the protocol or signature on informed consent

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention

Related Conditions & MeSH terms

• Influenza
• Influenza, Human

Intervention

Biological:
• Quadrivalent influenza vaccine
0.5 ml/vial, one dose, intramuscular injection on day 0
• Trivalent influenza vaccine A
0.5 ml/vial, one dose, intramuscular injection on day 0
• Trivalent influenza vaccine B
0.5 ml/vial, one dose, intramuscular injection on day 0

Locations

Country	Name	City	State
China	Guanyun County Center for Disease Control and Prevention	Lianyungang	Jiangsu

Sponsors (2)

Lead Sponsor	Collaborator
Jiangsu Province Centers for Disease Control and Prevention	Jiangsu Jindike Biotechnology Co., Ltd.

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	the 95% confidence interval (CI) lower limit for the seroconversion against each corresponding flu strain after vaccination is=40% in subjects aged 3-59 years and=30% in subjects aged =60 years separately	Immunogenicity outcomes were assessed in serum samples by Hemagglutination inhibition (HAI) assay. The lowest dilution used in the assay is 1/10. Seroconversion was defined as either a pre-vaccination HAI titer < 1:10 and a post-vaccination titer =1:40 or a pre-vaccination titer =1:10 and = four-fold increase in post-vaccination titer.	28 days after vaccination	No
Primary	incidence of solicited adverse reactions after vaccination	incidence of solicited adverse reactions (including systemic and local adverse reactions) after vaccination	0-7 days after vaccination	Yes
Secondary	the 95% CI lower limit for the post-vaccination seroprotection rates against each corresponding flu strain is =70%	A seroprotected subject is defined as a vaccinated subject with serum HAI titer= 1:40.	28 days after vaccination	No
Secondary	the post-vaccination mean geometric increases (GMIs) of HAI titer against each corresponding flu strain is=2.5 in subjects aged 3-59 years and=2.0 in subjects aged =60 years separately	Hemagglutination inhibition (HI) titers were used to calculate post-vaccination mean geometric increases (GMIs) of each of the influenza vaccines.	28 days after vaccination	No
Secondary	incidence of unsolicited adverse reactions after vaccination	incidence of unsolicited adverse reactions (including systemic and local adverse reactions) after vaccination	0-28 days after vaccination	Yes
Secondary	incidence of serious adverse event (SAE) after vaccination		0-28 days after vaccination	Yes
Secondary	incidence of serious adverse event (SAE) after vaccination		29 days to 6 month after vaccination	Yes